Dose banding as an alternative to body surface area-based dosing of chemotherapeutic agents

British Journal of Cancer

Volumn 107, Issue 7, 2012, Pages 1100-1106

  Chatelut, E ^a   White Koning, M L ^a   Mathijssen, R H ^b   Puisset, F ^a   Baker, S D ^c   Sparreboom, A ^c  

^a UNIVERSITÉ DE TOULOUSE   (France)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

anticancer drugs; chemotherapy; dose banding; dose standardisation; fixed dose

Indexed keywords

CAPECITABINE; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FIRTECAN; IRINOTECAN; MARIMASTAT; METHOTREXATE; PACLITAXEL; TOPOTECAN;

AREA UNDER THE CURVE; ARTICLE; BODY SURFACE; CANCER COMBINATION CHEMOTHERAPY; DOSE BANDING; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; HUMAN; MAJOR CLINICAL STUDY; MONOTHERAPY; NEOPLASM; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; BODY SURFACE AREA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; NEOPLASMS;

EID: 84866934611     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.357     Document Type: Article

References (17)

1. Berhoune M, Aboudagga H, Jacob A, Grandhaye JP, Dayot C, Prognon P, Bonan B (2011) Effect of requiring advance approval of chemotherapy on number and cost of ungiven doses. Am J Health Syst Pharm 68(7): 557-558
2. De Jong FA, Mathijssen RH, Xie R, Verweij J, Sparreboom A (2004) Flatfixed dosing of irinotecan: influence on pharmacokinetic and pharmacodynamic variability. Clin Cancer Res 10(12 Part 1): 4068-4071
3. De Jongh FE, Verweij J, Loos WJ, de WR, de Jonge MJ, Planting AS, Nooter K, Stoter G, Sparreboom A (2001) Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure. J Clin Oncol 19(17): 3733-3739
4. Deeken JF, Slack R, Marshall JL (2008) Irinotecan and uridine diphosphate glucuronosyltransferase 1A1 pharmacogenetics: to test or not to test, that is the question. Cancer 113(7): 1502-1510
5. Gurney H (1996) Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative. J Clin Oncol 14(9): 2590-2611
6. Henningsson A, Marsh S, Loos WJ, Karlsson MO, Garsa A, Mross K, Mielke S, Vigano L, Locatelli A, Verweij J, Sparreboom A, McLeod HL (2005) Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel. Clin Cancer Res 11(22): 8097-8104
7. Jodrell DI (1999) Formula-based dosing for carboplatin. Eur J Cancer 35(9): 1299-1301
8. Leger F, Loos WJ, Fourcade J, Bugat R, Goffinet M, Mathijssen RH, Verweij J, Sparreboom A, Chatelut E (2004) Factors affecting pharmacokinetic variability of oral topotecan: a population analysis. Br J Cancer 90(2): 343-347
9. Mathijssen RH, de Jong FA, Loos WJ, van der Bol JM, Verweij J, Sparreboom A (2007) Flat-fixed dosing versus body surface area based dosing of anticancer drugs in adults: does it make a difference? Oncologist 12(8): 913-923
10. Mathijssen RH, van Alphen RJ, Verweij J, Loos WJ, Nooter K, Stoter G, Sparreboom A (2001) Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res 7(8): 2182-2194
11. Pinkel D (1958) The use of body surface area as a criterion of drug dosage in cancer chemotherapy. Cancer Res 18(7): 853-856
12. Plumridge RJ, Sewell GJ (2001) Dose-banding of cytotoxic drugs: a new concept in cancer chemotherapy.AmJ Health Syst Pharm58(18): 1760-1764
13. Pouliquen AL, Escalup L, Jourdan N, Cottu P, Faure P, Madelaine-Chambrin I (2011) Dose standardisation of anticancer drugs. Int J Clin Pharm 33(2): 221-228
14. Reilly JJ, Workman P (1993) Normalisation of anti-cancer drug dosage using body weight and surface area: is it worthwhile? A review of theoretical and practical considerations. Cancer Chemother Pharmacol 32(6): 411-418
15. Rudek MA, Sparreboom A, Garrett-Mayer ES, Armstrong DK, Wolff AC, Verweij J, Baker SD (2004) Factors affecting pharmacokinetic variability following doxorubicin and docetaxel-based therapy. Eur J Cancer 40(8): 1170-1178
16. Sparreboom A (2005) BSA-based dosing and alternative approaches. Clin Adv Hematol Oncol 3(6): 448-450
17. Terret C, Erdociain E, Guimbaud R, Boisdron-Celle M, McLeod HL, Fety-Deporte R, Lafont T, Gamelin E, Bugat R, Canal P, Chatelut E (2000) Dose and time dependencies of 5-fluorouracil pharmacokinetics. Clin Pharmacol Ther 68(3): 270-279